431 related articles for article (PubMed ID: 15331931)
1. Combined therapy of cilazapril and losartan has no additive effects in ameliorating adriamycin-induced glomerulopathy.
Kim HJ; Ryu JH; Han SW; Park IK; Paik SS; Park MH; Paik DJ; Chung HS; Kim SW; Lee JU
Nephron Physiol; 2004; 97(4):p58-65. PubMed ID: 15331931
[TBL] [Abstract][Full Text] [Related]
2. Effects of angiotensin converting enzyme inhibitor, angiotensin II type I receptor blocker and their combination on postinfarcted ventricular remodeling in rats.
Zhang RY; Wang LF; Zhang L; Meng XN; Li SJ; Wang WR
Chin Med J (Engl); 2006 Apr; 119(8):649-55. PubMed ID: 16635409
[TBL] [Abstract][Full Text] [Related]
3. Renin-angiotensin system blockade prevents the increase in plasma transforming growth factor beta 1, and reduces proteinuria and kidney hypertrophy in the streptozotocin-diabetic rat.
Erman A; Veksler S; Gafter U; Boner G; Wittenberg C; van Dijk DJ
J Renin Angiotensin Aldosterone Syst; 2004 Sep; 5(3):146-51. PubMed ID: 15526251
[TBL] [Abstract][Full Text] [Related]
4. [Relativity of nuclear factor-kappaB (P65/Rel-A) and angiotensin II type 1 receptor expression in early stage of lesions of adriamycin nephrosis in young rats and the effects of intervention].
Ma H; Li Z; Meng QH; Li XH; Wang XH; Li H; Li WW
Zhonghua Er Ke Za Zhi; 2004 Apr; 42(4):275-9. PubMed ID: 15157388
[TBL] [Abstract][Full Text] [Related]
5. Low-dose dual blockade of the renin-angiotensin system improves tubular status in non-diabetic proteinuric patients.
Renke M; Tylicki L; Rutkowski P; Wojnarowski K; Lysiak-Szydlowska W; Rutkowski B
Scand J Urol Nephrol; 2005; 39(6):511-7. PubMed ID: 16303729
[TBL] [Abstract][Full Text] [Related]
6. Protective effects of blocking renin-angiotensin system on the progression of renal injury in glomerulosclerosis.
Ji Z; Huang C; Liang C; Chen B; Chen S; Sun W
Cell Mol Immunol; 2005 Apr; 2(2):150-4. PubMed ID: 16191423
[TBL] [Abstract][Full Text] [Related]
7. Dual blockade of the renin-angiotensin-aldosterone system with high-dose angiotensin-converting enzyme inhibitor for nephroprotection: an open, controlled, randomized study.
Tylicki L; Renke M; Rutkowski P; Larczyński W; Aleksandrowicz E; Lysiak-Szydlowska W; Rutkowski B
Scand J Urol Nephrol; 2008; 42(4):381-8. PubMed ID: 19230172
[TBL] [Abstract][Full Text] [Related]
8. Diuretic uptitration with half dose combined ACEI + ARB better decreases proteinuria than combined ACEI + ARB uptitration.
Esnault VL; Ekhlas A; Nguyen JM; Moranne O
Nephrol Dial Transplant; 2010 Jul; 25(7):2218-24. PubMed ID: 20106824
[TBL] [Abstract][Full Text] [Related]
9. Blocking angiotensin II ameliorates proteinuria and glomerular lesions in progressive mesangioproliferative glomerulonephritis.
Nakamura T; Obata J; Kimura H; Ohno S; Yoshida Y; Kawachi H; Shimizu F
Kidney Int; 1999 Mar; 55(3):877-89. PubMed ID: 10027924
[TBL] [Abstract][Full Text] [Related]
10. Effects of dual blockade of renin-angiotensin system in type 2 diabetes mellitus patients with diabetic nephropathy.
Krairittichai U; Chaisuvannarat V
J Med Assoc Thai; 2009 May; 92(5):611-7. PubMed ID: 19459520
[TBL] [Abstract][Full Text] [Related]
11. Angiotensin receptor blocker reduces proteinuria independently of blood pressure in children already treated with Angiotensin-converting enzyme inhibitors.
Seeman T; Pohl M; Misselwitz J; John U
Kidney Blood Press Res; 2009; 32(6):440-4. PubMed ID: 20016211
[TBL] [Abstract][Full Text] [Related]
12. Adding a statin to a combination of ACE inhibitor and ARB normalizes proteinuria in experimental diabetes, which translates into full renoprotection.
Zoja C; Corna D; Gagliardini E; Conti S; Arnaboldi L; Benigni A; Remuzzi G
Am J Physiol Renal Physiol; 2010 Nov; 299(5):F1203-11. PubMed ID: 20719975
[TBL] [Abstract][Full Text] [Related]
13. Renin angiotensin system blockade ameliorates lead nephropathy.
Ng HY; Tain YL; Lee YT; Hsu CY; Chiou TT; Huang PC; Lee CT
Biochem Biophys Res Commun; 2013 Aug; 438(2):359-63. PubMed ID: 23896603
[TBL] [Abstract][Full Text] [Related]
14. Effect of renin-angiotensin-aldosterone system triple blockade on non-diabetic renal disease: addition of an aldosterone blocker, spironolactone, to combination treatment with an angiotensin-converting enzyme inhibitor and angiotensin II receptor blocker.
Furumatsu Y; Nagasawa Y; Tomida K; Mikami S; Kaneko T; Okada N; Tsubakihara Y; Imai E; Shoji T
Hypertens Res; 2008 Jan; 31(1):59-67. PubMed ID: 18360019
[TBL] [Abstract][Full Text] [Related]
15. Angiotensin-converting enzyme inhibition and AT1 receptor blockade modify the pressure-natriuresis relationship by additive mechanisms in rats with human renin and angiotensinogen genes.
Mervaala E; Dehmel B; Gross V; Lippoldt A; Bohlender J; Milia AF; Ganten D; Luft FC
J Am Soc Nephrol; 1999 Aug; 10(8):1669-80. PubMed ID: 10446934
[TBL] [Abstract][Full Text] [Related]
16. Regression of glomerulosclerosis with high-dose angiotensin inhibition is linked to decreased plasminogen activator inhibitor-1.
Ma LJ; Nakamura S; Aldigier JC; Rossini M; Yang H; Liang X; Nakamura I; Marcantoni C; Fogo AB
J Am Soc Nephrol; 2005 Apr; 16(4):966-76. PubMed ID: 15728787
[TBL] [Abstract][Full Text] [Related]
17. No impact of hyperkalaemia with renin-angiotensin system blockades in maintenance haemodialysis patients.
Han SW; Won YW; Yi JH; Kim HJ
Nephrol Dial Transplant; 2007 Apr; 22(4):1150-5. PubMed ID: 17255126
[TBL] [Abstract][Full Text] [Related]
18. Renoprotective effect of early inhibition of the renin-angiotensin system in renal transplant recipients.
Montanaro D; Gropuzzo M; Tulissi P; Vallone C; Boscutti G; Mioni R; Risaliti A; Baccarani U; Adani GL; Sainz M; Bresadola F; Mioni G
Transplant Proc; 2005 Mar; 37(2):991-3. PubMed ID: 15848600
[TBL] [Abstract][Full Text] [Related]
19. [The effects of renin-angiotensin system blockade on the liver steatosis in rats on long-term high-fat diet].
Chen YH; Yuan L; Chen YY; Qi CJ
Zhonghua Nei Ke Za Zhi; 2008 Mar; 47(3):197-201. PubMed ID: 18785501
[TBL] [Abstract][Full Text] [Related]
20. Triple pharmacological blockade of the renin-angiotensin-aldosterone system in nondiabetic CKD: an open-label crossover randomized controlled trial.
Tylicki L; Rutkowski P; Renke M; Larczyński W; Aleksandrowicz E; Lysiak-Szydlowska W; Rutkowski B
Am J Kidney Dis; 2008 Sep; 52(3):486-93. PubMed ID: 18423812
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
